Julie Désir

Julie Désir

Auto-generated profile, based on publicly available information

Julie Désir

Erasmus Hospital Human Genetics Brussels Belgium

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in European Journal of Neurology
Verified
Journal Article
Closed access
ADAnne Dompmartin
Anne Dompmartin
CVCarine J. M. van der Vleuten
Carine J. M. van der Vleuten
VDValérie Dekeuleneer
Valérie Dekeuleneer
TDThierry Duprez
Thierry Duprez
NRNicole Revencu
Nicole Revencu
LBLaurence Boon
Laurence Boon

25 February 2015 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
NCNicolas Chatron
Nicolas Chatron
VHVéronique Haddad
Véronique Haddad
JAJoris Andrieux
Joris Andrieux
JDJulie Désir
Julie Désir
OBOdile Boute
Odile Boute
CSCaroline Schluth‐Bolard
Caroline Schluth‐Bolard

11 April 2012 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
JDJulie Désir
Julie Désir
MCMarie Cassart
Marie Cassart
CDCatherine Donner
Catherine Donner
PCPaul Coucke
Paul Coucke
MAMarc Abramowicz
Marc Abramowicz
GMGeert Mortier
Geert Mortier
We describe a fetus with platyspondylic lethal skeletal dysplasia, Torrance type (PLSD‐T), a rare skeletal dysplasia characterized by platyspondyly, extremely short limbs, and mild brachydactyly. Mutation analysis of COL2A1 identified a novel in‐frame deletion c.4458_4460delCTT (p.Phe1486del) in the C‐propeptide region of the molecule, confirming the clinical diagnosis. The phenotype in the mother was compatible with mild spondyloperipheral dysplasia (SPPD). Molecular studies documented somatic mosaicism for the same mutation in the mother. This observation further highlights the causal relationship between PLSD‐T and SPPD and emphasizes the importance of evaluating parents when confronted with a skeletal dysplasia in a prenatal setting.

1 December 2020 in F&S Reports
Verified
Journal Article
Open access
ASAsma Sassi
Asma Sassi
JDJulie Désir
Julie Désir
VJVéronique Janssens
Véronique Janssens
MMMartina Marangoni
Martina Marangoni
DDDorien Daneels
Dorien Daneels
ADAnne Delbaere
Anne Delbaere
To find the genetic etiology of premature ovarian insufficiency (POI) in a patient with primary amenorrhea and hypergonadotropic hypogonadism. Case report. University hospital. A Belgian woman aged 32 years with POI at the age of 17, her parents, and her sister whose POI was diagnosed at age 29. Analysis of a panel of 31 genes implicated in POI (POIGP) using next-generation sequencing (NGS), Sanger sequencing, and in vitro functional study. Gene variants, family mutational segregation, and in vitro functional impact of the mutant proteins. The analysis of the gene panel using NGS identified the presence of two novel follicle-stimulating hormone receptor (FSHR) missense mutations at a compound heterozygous state in the affected patient: c.646 G>A, p.Gly216Arg, and c.1313C>T, p.Thr438Ile. Sanger sequencing showed the presence of each mutation at heterozygous state in the patient’s parents and at heterozygous compound state in the affected sister. Both substituted amino acids (Gly216 and Thr438) were conserved in FSHR of several vertebrate species as well as in other glycoproteins receptors (TSHR and LHCGHR), suggesting a potentially important role in glycoprotein receptor function. An in vitro functional study showed similar results for both variants with more than 90% reduction of their cell surface expression and a 55% reduction of their FSH-induced cyclic adenosine 3′:5′ monophosphate (cAMP) production compared with the wild-type FSHR. The analysis of a gene panel of 31 genes implicated in POI allowed us to identify two novel partially inactivating mutations of FSHR that are likely responsible for the POI phenotype of the proband and of her affected sister.